Loading clinical trials...
Loading clinical trials...
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS 9190, in Combination With Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection (GS-US-196-0103)
Conditions
Interventions
placebo
GS-9190
+2 more
Locations
72
United States
Anaheim, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
San Clemente, California, United States
San Diego, California, United States
San Diego, California, United States
Start Date
October 1, 2008
Primary Completion Date
July 1, 2009
Completion Date
September 1, 2013
Last Updated
November 5, 2013
NCT06928259
NCT05992077
NCT05534633
NCT07412977
NCT07241962
NCT04134767
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions